CancerFax

China to open borders for patients travelling for medical treatment

Dr. Nishant  MittalWritten by Dr. Nishant MittalMedically ReviewedUpdated March 14, 20233 min read
China to open borders for patients travelling for medical treatment
In this article
  1. China Reopens Borders for International Medical Patients
  2. Visa Policy Updates and Economic Recovery in China
  3. International Travel Statistics and Border Crossing Trends
  4. CAR T-Cell Therapy and Cancer Clinical Trials in China
  5. How CancerFax Helps

China Reopens Borders for International Medical Patients

Beijing, March 14, 2023: There is good news for patients travelling to China for advanced cancer treatment and the latest therapies like CAR T-cell therapy, Cilta-Cel therapy, and even for clinical trials in advanced cancer treatment. China will reopen its borders to foreign tourists on Wednesday for the first time since the outbreak of the COVID-19 pandemic three years ago by resuming the issuance of all types of visas.

The removal of this final border control measure imposed to combat COVID-19 comes after authorities declared victory over a recent outbreak of the virus last month.

Visa Policy Updates and Economic Recovery in China

The boost to the tourism industry should assist in reviving a $17 trillion economy that experienced one of its slowest growth rates in nearly half a century last year.

China’s foreign ministry announced on Tuesday that areas that did not require visas before the pandemic will again be visa-free. This includes the southern tourist island of Hainan and cruise ships docking at Shanghai port.

Hong Kong and Macau's visa-free entry to the southern manufacturing hub of Guangdong will also be reinstated.

Foreign nationals with valid visas issued before March 28, 2020, will also be permitted to enter China, according to the ministry.

In January, China lifted its warning against foreign travel for its citizens and added 40 more countries to its list of countries where group tours are permitted, bringing the total to 60.

You may like to read: CAR T-Cell therapy in China

International Travel Statistics and Border Crossing Trends

According to the Chinese flight tracking application Flight Master, the number of inbound and outbound international flights during the week of March 6 increased by more than 350% compared to the previous year, reaching nearly 2,500 flights. However, this number was still only 17.4% of 2019 levels.

In 2022, there were only 115.7 million border crossings into and out of China, with foreigners accounting for approximately 4.5 million.

In contrast, China recorded 670 million international trips in 2019, of which 97.7 million were made by foreigners.

Beijing abandoned its draconian zero-COVID policies in December, and quarantine requirements for incoming travelers were eliminated in January.

CAR T-Cell Therapy and Cancer Clinical Trials in China

CAR T-cell therapy in China has grown at a very rapid rate, and currently, there are more than 750 clinical trials being conducted in China on different types of cancer. Clinical trials for advanced-stage colon cancer are ongoing in some of the leading cancer hospitals in China.

CAR T-Cell Therapy in China

How CancerFax Helps

CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.

description
Medical Record Review

We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.

verified_user
Eligibility Coordination

We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.

hub
Hospital Communication

We support appointment coordination, document submission, translation, and direct communication with international departments.

flight
Travel & Admission Support

For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.

explore
Treatment & Trial Navigation

If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.

support_agent
End-to-end Coordination

From inquiry through to follow-up, our coordinators provide a single point of contact for the family.

CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.

Dr. Nishant  Mittal

About Dr. Nishant Mittal

Dr. Nishant Mittal is a highly accomplished researcher with over 13 years of experience in the fields of cardiovascular biology and cancer research. Significant contributions to stem cell biology, developmental biology, and innovative research techniques mark his career. Research Highlights Dr. Mittal's research has focused on several key areas: 1) Cardio…

✓ Reviewed for medical accuracy by the CancerFax review panel.

Medical Disclaimer

This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.

Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.